These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2977108)

  • 1. Teicoplanin: an investigational glycopeptide antibiotic.
    Pryka RD; Rodvold KA; Rotschafer JC
    Clin Pharm; 1988 Sep; 7(9):647-58. PubMed ID: 2977108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic characteristics and antimicrobial spectrum of teicoplanin].
    Paganini H; Marin M
    Medicina (B Aires); 2002; 62 Suppl 2():52-5. PubMed ID: 12481490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teicoplanin: a new glycopeptide antibiotic complex.
    Babul N; Pasko M
    Drug Intell Clin Pharm; 1988 Mar; 22(3):218-26. PubMed ID: 2966729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Origin, structure, and activity in vitro and in vivo of dalbavancin.
    Malabarba A; Goldstein BP
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii15-20. PubMed ID: 15750032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microbiological-clinical study on the efficacy of a new antibiotic: teicoplanin].
    Martinetto P; Gariglio M; Malcangi A; Cavallo GP
    G Batteriol Virol Immunol; 1985; 78(1-6):86-94. PubMed ID: 2943627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teicoplanin vs vancomycin: cost-effectiveness comparisons.
    Rybak MJ
    Hosp Formul; 1993 Jan; 28 Suppl 1():28-32. PubMed ID: 10123835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC; Sader HS; Jones RN
    Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Teicoplanin in the prophylaxis of surgical infections and bacterial endocarditis].
    Nacinovich F; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():36-9. PubMed ID: 12481487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surveillance of gram positive cocci susceptibility to betalactams, glycopeptides, and other antimicrobials].
    Giglio MS; Farías O; Lafourcade M; Pinto ME
    Rev Med Chil; 1999 Aug; 127(8):919-25. PubMed ID: 10752252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
    Crane VS; Garabedian-Ruffalo SM
    Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapeutic strategies with teicoplanin].
    Carbone E; Nacinovich F; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():25-9. PubMed ID: 12481485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci.
    Bourgeois I; Pestel-Caron M; Lemeland JF; Pons JL; Caron F
    Antimicrob Agents Chemother; 2007 Feb; 51(2):740-3. PubMed ID: 17116684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycopeptides: Update on an old successful antibiotic class.
    Pace JL; Yang G
    Biochem Pharmacol; 2006 Mar; 71(7):968-80. PubMed ID: 16412985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.